Daptomycin
A cyclic lipopeptide antibiotic that inserts into and disrupts Gram-positive bacterial cell membranes, causing rapid cell death; used intravenously for skin infections and bloodstream infections caused by MRSA and vancomycin-resistant enterococcus. It cannot be used for pneumonia because lung surfactant inactivates it.
Berat Molekul
1620,7000 g/mol
LogP
-5,10
TPSA
702,00 Ų
Lipinski RO5
Gagal
Area Terapeutik
Mekanisme Kerja
Reduces surface tension at the air-liquid interface in the pulmonary alveoli, preventing alveolar collapse during expiration and improving lung compliance and gas exchange.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Reduces surface tension at the air-liquid interface in the pulmonary alveoli, preventing alveolar collapse during expiration and improving lung compliance and gas exchange.
Struktur 2D
Cite this structure
Embed this structure
SMILES
CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@@H]([C@H](C)CC(=O)O)C(=O)N[C@@H](CC(=O)c2ccccc2N)C(=O)O[C@@H]1C
InChI
InChI=1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37-,43+,44+,45+,46+,47+,48+,49+,50-,60+,61+/m1/s1
Molecular Formula
C72H101N17O26
HBD / HBA
22 / 28
Ikatan yang Dapat Dirotasi
35
Atom Berat
115
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Pertanyaan yang Sering Diajukan
A cyclic lipopeptide antibiotic that inserts into and disrupts Gram-positive bacterial cell membranes, causing rapid cell death; used intravenously for skin infections and bloodstream infections caused by MRSA and vancomycin-resistant enterococcus. It cannot be used for pneumonia because lung surfactant inactivates it.
Reduces surface tension at the air-liquid interface in the pulmonary alveoli, preventing alveolar collapse during expiration and improving lung compliance and gas exchange.
Yes, Daptomycin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL387675. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 21585658. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="daptomycin"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/daptomycin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/daptomycin/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/daptomycin/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="daptomycin"></drugfyi-drug>